Research Project 1 (RP1) builds on the progress and success of Projects 1 and 2 in ICMIC-2. Our hypothesis is that both constitutive and PSMA-activated reporter gene imaging of PSMA directed T cell targeting, distribution and persistence can be performed concurrently in patients with castrate resistant prostate cancer. The central theme of this proposal is consistent with our ICMIC:
Project 1 involves a phase 1 clinical study to test whether genetically altered, PSMA directed, T cells can be monitored by non-invasive Positron Emission Tomography (PET) imaging, and whether the imaging results can provide an early indication of treatment response (or failure) in patients with castrate resistant prostate cancer. In parallel, preclinical imaging studies will evaluate the effect of an abnormal tumor microenvironment and the effect of tumor PSMA expression levels on: 1) PSMA-directed T cell targeting, activation and persistence, and on 2) the efficacy of tumor-modulated, PSMA-directed T cell therapy. Importantly, these imaging studies could be readily translated to clinic and serve as a model to study other cancers.
Showing the most recent 10 out of 191 publications